INTRODUCTION
Gadolinium-based contrast agents are extensively used in magnetic resonance imaging (MRI) of the brain. Occasionally, these agents are associated with minimal neurotoxicity. However, several reports of increased signal intensity in the subarachnoid space have been reported in patients with end-stage renal failure due to the deposition of gadolinium in the cerebrospinal fluid (CSF), following the use of a gadolinium chelate as the contrast medium. Here, we report a patient admitted to our emergency room with an acute cerebral infarction, whose enhancement brain MRI revealed high signal intensity in the CSF spaces on follow-up fluid-attenuated inversion recovery (FLAIR) images, which could have led to a misdiagnosis.
CASE REPORT
An 81-year-old woman was admitted to our emergency room with a 4-hour history of aphasia and right hemiparesis. Her medical history was significant for diabetes and hypertension, for which she was undergoing treatment. She underwent brain MRI with gadolinium-based contrast medium. During the study, 30 mL of gadopentetate dimeglumine (Uniray, Dongkook Pharmaceutical Co., Ltd, Seoul, Korea) was administered, to obtain perfusion MRI and contrast-enhanced neck MR angiography.
Diffusion and perfusion MRI revealed multifocal acute infarctions in the left frontal lobe, basal ganglia, and insular cortex, with diffusion-perfusion mismatch ( Fig. 1A-C ). Magnetic resonance angiography revealed stenosis in the left M1 and M2 segments. At the time of admission, the patient had a creatinine A gadolinium-based contrast is the preferred agent when differentiating acute neurological diseases. Since the renal route is the main pathway for excretion of gadolinium chelates, prolonged extracellular distribution of gadolinium has previously been reported in dialysis-dependent patients. Hence, gadolinium-based contrast agents are used cautiously in patients with known renal disease. Retention of gadolinium manifests as increased fluid-attenuated inversion recovery (FLAIR) signal intensity in the subarachnoid space, leading to diagnostic errors. Here, we describe a patient who presented to our emergency room with an acute cerebral infarction. Enhanced brain magnetic resonance imaging performed 2 days later revealed high signal intensity in the cerebrospinal fluid spaces on follow-up FLAIR images. Gadolinium is an extracellular contrast medium, and its elimination is mainly via the glomerular route, which is likely to be affected by renal impairment (4) . In patients with normal renal function, the mean half-life of gadolinium was reported to be 1.5 hours, but increased to 34.3 ± 22.9 hours in patients with severe renal insufficiency who received gadolinium 0.1 mmol/ kg (4) . Another paper reports a patient with renal impairment, in whom the contrast medium was retained for more than 2 weeks after injection (3) . A prolonged elevated concentration increases the availability of gadolinium in plasma (2) , and its persistence in the circulation leads to release of free gadolinium.
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This free gadolinium has been reported to cause neurotoxicity (5). The mechanism via which gadolinium enters the CSF spac- The major limitation of our study is the lack of inclusion of a mass spectrometry or CSF study to demonstrate changes in gadolinium levels in the serum and CSF. The correlation between MRI findings and these indices need to be further investigated. 
